Prof. Alena Buyx heads the Institute for the History and Ethics of Medicine at TUM and has been Chair of the German Ethics Council since Spring 2020.
Prof. Alena Buyx heads the Institute for the History and Ethics of Medicine at TUM and has been Chair of the German Ethics Council since Spring 2020.
Image: A. Heddergott
  • Covid-19
  • Reading time: 3 MIN

Medical ethicist Alena Buyx: Consider differences in efficacy when allocating vaccineFair allocation in times of pandemic

At present Germany's elderly are being given priority for Covid-19 vaccination. But what happens when only minimal research data is available on the effects new vaccines have on the elderly? Such circumstances should play a role in ethical considerations of fairness in distributing scarce medical resources, says Alena Buyx, Chair of the German Ethics Council, in the Technical University of Munich (TUM)'s "Covid-19 Lecture Series". Buyx is professor for Ethics in Medicine and Health Technologies at TUM.

"The whole world wants a vaccine. And at first – as was to be expected – there isn't enough to go around. A situation like this where the vaccine is absolutely scarce calls for proper prioritization," said Buyx. The vaccines against Sars-CoV-2 approved in Germany are therefore being allocated according to a five-tier prioritization model. Since the risk of a severe or fatal Covid-19 infection is 500 times higher for people over the age of 80 than for the young and healthy population, the elderly are currently very high on the allocation list. However, allocation in practice could change in case of new vaccines.

„The ethical difficulties are often a matter of detail.”— Prof. Alena Buyx

Buyx said that there are enormous challenges involved when it comes to practically implementing the ethical guidelines she has carefully formulated together with the members of the German Ethics Council, the Standing Committee on Vaccination (STIKO) and the Leopoldina German National Academy of Sciences. One example is the vaccine from AstraZeneca approved on Friday by the European Medicines Agency (EMA). According to STIKO the available data on the vaccine's efficacy for those over 65 years of age are insufficient. Buyx said that possible differences in the efficacy of a vaccine for different age groups have to be considered in vaccine distribution.

The medical ethicist went on to say that the reason primarily the elderly are being vaccinated is the basic principle of recognizing under the law not only the equality of all people, but also their differences. "An individual with an entirely different risk level may also receive different treatment," she added, noting that nevertheless the practical guidelines resulting from legal-ethical prerequisites require constant adaptation and ongoing further development – especially when important medical data are not yet available. "The ethical difficulties are often a matter of detail," said Buyx.

„We're in a very steep learning curve.”— Prof. Alena Buyx

The lack of reliable data is however also relevant in another context, as when it comes to the fair distribution of vaccines, she said. Buyx noted for example that at present it cannot be assumed with certainty that vaccinated individuals will not nevertheless infect others with the virus. If it was certain, she said, that by being vaccinated younger people could protect older people against infection, the fact would also have an impact on prioritization. "We're in a very steep learning curve," said Buyx. She pointed out that the most important factor in vaccine allocation is that it has to be transparent, robust and understandable; this can in turn inspire trust. Of course, it will never be possible to design the allocation process so that everyone will be satisfied, she conceded.

In her lecture Buyx also spoke on triage, i.e. the prioritization of patients requiring acute treatment in cases where medical capacities are inadequate. While triage happily still remains a theoretical consideration in Germany, the German Ethics Council and its Chair Alena Buyx are developing recommendations for vaccine allocation as the basis for current policy decisions. "I find the situation in part fairly bizarre," said the medical ethicist. During almost 20 years working with the allocation of scarce medical resources, Buyx said, she has often been asked why she was dealing with such a theoretical topic. But since early 2020 the topic has become highly relevant and could hardly have a more pragmatic focus.

Technical University of Munich

Corporate Communications Center Lisa Pietrzyk
lisa.pietrzyk(at)tum.de

Article at tum.de

Portrait of Prof. Martin Boeker, Prof. Alena Buyx und Prof. Dirk Heckmann

"Health data are important for pandemic control"

On May 5, Martin Boeker, Professor for Medical Informatics, Alena Buyx, Professor for Ethics in Medicine and Health Technologies and Chair of the German Ethics Council, and Dirk Heckmann, Professor for Law and Security in...

Prof. Percy Knolle, director of the Institute of Molecular Immunology at TUM

"The infection needs to be controlled at an early stage"

The Covid-19 Lectures, a public online lecture series in German language, open on April 14 at 6:15 p.m. with a talk by Prof. Percy Knolle. In this interview the director of the Institute of Molecular Immunology at TUM...

[Translate to en:]

"Antivirally effective drugs are in the development pipeline"

On April 21, Ulrike Protzer, director of the Institute of Virology, and Andreas Pichlmair, Professor of Viral Immunopathology, will give the Covid-19 Lecture on virus-host interaction. Ahead of the event, Prof. Protzer...

Sport can prevent severe Covid-19 courses

Dr. Fritz Wimbauer is a senior physician at the Polyclinic for Preventive and Rehabilitative Sports Medicine at TUM's university hospitalm rechts der Isar and head of the outpatient clinic at Georg-Brauchle-Ring. In an...

COVID-19: Perspectives on current research

As the past year has shown, science is central to dealing with and combating the Corona pandemic. Researchers are constantly creating new knowledge about the virus, advising policymakers and industry on medical, ethical and...

Prof. Lothar H. Wieler, President of the Robert Koch Institute.

Munich Talk with the President of the Robert Koch Institute

The President of the Robert Koch Institute will speak at the Munich Talks, hosted by the Bavarian School of Public Policy (HfP) / TUM School of Governance, on March 11. Prof. Lothar H. Wieler will offer insights into the...

Woman with mouth-nose protection in empty airport terminal

Largest database on Covid-19 measures available online

A research group has built the world’s largest database on political decisions related to the coronavirus pandemic. With CoronaNet data on approximately 50,000 measures taken in 195 countries, some down to the municipal...

A blond woman is standing in a corridor smiling directly to the camera

"Ethics must be part of the development process"

The increasing use of AI (artificial intelligence) in the development of new medical technologies demands greater attention to ethical aspects. An interdisciplinary team at the Technical University of Munich (TUM) advocates...

Alena Buyx is a professor for Ethics in Medicine and Health Technologies and Director of the Institute of History and Ethics in Medicine at TUM.

Alena Buyx is new Chair of the German Ethics Council

Following the appointment of several new members to the German Ethics Council in April 2020, Alena Buyx was elected the new Chair of the body at its inaugural meeting on May 28, 2020. Alena Buyx is a professor for Ethics in...

Prof. Alena Buyx

Robot therapists need rules

Interactions with artificial intelligence (AI) will become an increasingly common aspect of our lives. A team at the Technical University of Munich (TUM) has now completed the first study of how “embodied AI” can help treat...